INNATE PHARMA EUR0.05 (NASDAQ:IPHYF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday.

According to Zacks, “Innate Pharma S.A. is a biopharmaceutical company. It develops drugs for treatment of cancer and inflammatory diseases. The company specializes in the development of first-in-class therapeutic antibodies targeting receptors and pathways controlling the activation of the innate immune system. Innate Pharma S.A. is headquartered in Marseilles, France. “

Separately, Leerink Swann restated a “buy” rating on shares of INNATE PHARMA EUR0.05 in a research report on Wednesday, August 17th.

INNATE PHARMA EUR0.05 (NASDAQ:IPHYF) opened at 14.002 on Wednesday. The company’s market cap is $754.39 million. The firm has a 50-day moving average price of $12.19 and a 200-day moving average price of $12.50. INNATE PHARMA EUR0.05 has a 12-month low of $10.36 and a 12-month high of $15.58.

5 Day Chart for NASDAQ:IPHYF

Receive News & Stock Ratings for INNATE PHARMA EUR0.05 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INNATE PHARMA EUR0.05 and related stocks with our FREE daily email newsletter.